Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVDD in Newly Diagnosed Multiple Myeloma
NCT00750815Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2008
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide in multiple myeloma (MM) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Planned Dose at 9 months and Overall Response Rate up to 6 months. Started Sep 2008; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00750815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750815.